Adhera Therapeutics

ATRX

Medical - Pharmaceuticals · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$722

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+325.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 542K (2018) → 2.3M (2022)

Adhera Therapeutics is a small biotechnology company focused on developing drug treatments for serious diseases. It has worked on therapies targeting conditions such as HIV-related complications and certain cancers. The company does not sell consumer products — it works in clinical-stage drug development, meaning its medicines are still being tested and have not yet reached widespread commercial use.

Adhera generates little to no revenue at this stage, which is typical for early-stage biotech companies that spend money on research before any product is approved and sold. It operates primarily in the United States and carries a very small market capitalization, reflecting the high uncertainty around its pipeline. The biggest risk the company faces is running out of cash before it can advance its drug candidates through clinical trials and regulatory approval — a common challenge for micro-cap biotechs with no commercial product on the market.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-45.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

Research and development spending

Insider Activity

7.2%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~3 months

$32,388 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Adhera Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial